An Association between Bevacizumab and Recurrent Posterior Reversible Encephalopathy Syndrome in a Patient Presenting with Deep Vein Thrombosis: A Case Report and Review of the Literature
Background. The posterior reversible encephalopathy syndrome (PRES) is a syndrome characterized by hypertension, headache, seizures, and visual disturbances. Causes of PRES include preeclampsia/eclampsia, hypertension, and recently bevacizumab, a monoclonal antibody vascular endothelial growth facto...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2012/819546 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558039128866816 |
|---|---|
| author | Mark Lazarus Stanley Amundson Rajesh Belani |
| author_facet | Mark Lazarus Stanley Amundson Rajesh Belani |
| author_sort | Mark Lazarus |
| collection | DOAJ |
| description | Background. The posterior reversible encephalopathy syndrome (PRES) is a syndrome characterized by hypertension, headache, seizures, and visual disturbances. Causes of PRES include preeclampsia/eclampsia, hypertension, and recently bevacizumab, a monoclonal antibody vascular endothelial growth factor (VEGF) inhibitor. There is no information to date about PRES recurrence in patients taking bevacizumab or descriptions of deep vein thrombosis (DVT) in the setting of PRES. We reviewed data on a patient receiving bevacizumab who presented with a DVT and PRES and later developed recurrent PRES. Case. A 72-year-old man with metastatic pulmonary adenocarcinoma received maintenance bevacizumab following six cycles of carboplatin and paclitaxel. Following his eighth dose of bevacizumab, he developed a DVT as well as PRES. He made a rapid recovery and was discharged from the hospital but went on to develop PRES recurrence nine days following his original episode. Conclusion. Several mechanisms exist whereby exposure to bevacizumab could be related to the development of both DVT and PRES by inducing global endothelial dysfunction. Recurrent PRES may result from bevacizumab’s prolonged half-life (11–50 days) and suboptimal blood pressure control. In the setting of bevacizumab, PRES surveillance may play a similar role in preeclampsia screening as both diseases share similar antiangiogenic signaling pathways. |
| format | Article |
| id | doaj-art-720a2a6cabdd4a509cc04a4e46fbd931 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-720a2a6cabdd4a509cc04a4e46fbd9312025-02-03T01:33:25ZengWileyCase Reports in Oncological Medicine2090-67062090-67142012-01-01201210.1155/2012/819546819546An Association between Bevacizumab and Recurrent Posterior Reversible Encephalopathy Syndrome in a Patient Presenting with Deep Vein Thrombosis: A Case Report and Review of the LiteratureMark Lazarus0Stanley Amundson1Rajesh Belani2Office of Medical Education, 4077 5th Avenue, San Diego, CA 92103, USAOffice of Medical Education, 4077 5th Avenue, San Diego, CA 92103, USA3075 Health Center Drive, Suite 102, San Diego, CA 92123, USABackground. The posterior reversible encephalopathy syndrome (PRES) is a syndrome characterized by hypertension, headache, seizures, and visual disturbances. Causes of PRES include preeclampsia/eclampsia, hypertension, and recently bevacizumab, a monoclonal antibody vascular endothelial growth factor (VEGF) inhibitor. There is no information to date about PRES recurrence in patients taking bevacizumab or descriptions of deep vein thrombosis (DVT) in the setting of PRES. We reviewed data on a patient receiving bevacizumab who presented with a DVT and PRES and later developed recurrent PRES. Case. A 72-year-old man with metastatic pulmonary adenocarcinoma received maintenance bevacizumab following six cycles of carboplatin and paclitaxel. Following his eighth dose of bevacizumab, he developed a DVT as well as PRES. He made a rapid recovery and was discharged from the hospital but went on to develop PRES recurrence nine days following his original episode. Conclusion. Several mechanisms exist whereby exposure to bevacizumab could be related to the development of both DVT and PRES by inducing global endothelial dysfunction. Recurrent PRES may result from bevacizumab’s prolonged half-life (11–50 days) and suboptimal blood pressure control. In the setting of bevacizumab, PRES surveillance may play a similar role in preeclampsia screening as both diseases share similar antiangiogenic signaling pathways.http://dx.doi.org/10.1155/2012/819546 |
| spellingShingle | Mark Lazarus Stanley Amundson Rajesh Belani An Association between Bevacizumab and Recurrent Posterior Reversible Encephalopathy Syndrome in a Patient Presenting with Deep Vein Thrombosis: A Case Report and Review of the Literature Case Reports in Oncological Medicine |
| title | An Association between Bevacizumab and Recurrent Posterior Reversible Encephalopathy Syndrome in a Patient Presenting with Deep Vein Thrombosis: A Case Report and Review of the Literature |
| title_full | An Association between Bevacizumab and Recurrent Posterior Reversible Encephalopathy Syndrome in a Patient Presenting with Deep Vein Thrombosis: A Case Report and Review of the Literature |
| title_fullStr | An Association between Bevacizumab and Recurrent Posterior Reversible Encephalopathy Syndrome in a Patient Presenting with Deep Vein Thrombosis: A Case Report and Review of the Literature |
| title_full_unstemmed | An Association between Bevacizumab and Recurrent Posterior Reversible Encephalopathy Syndrome in a Patient Presenting with Deep Vein Thrombosis: A Case Report and Review of the Literature |
| title_short | An Association between Bevacizumab and Recurrent Posterior Reversible Encephalopathy Syndrome in a Patient Presenting with Deep Vein Thrombosis: A Case Report and Review of the Literature |
| title_sort | association between bevacizumab and recurrent posterior reversible encephalopathy syndrome in a patient presenting with deep vein thrombosis a case report and review of the literature |
| url | http://dx.doi.org/10.1155/2012/819546 |
| work_keys_str_mv | AT marklazarus anassociationbetweenbevacizumabandrecurrentposteriorreversibleencephalopathysyndromeinapatientpresentingwithdeepveinthrombosisacasereportandreviewoftheliterature AT stanleyamundson anassociationbetweenbevacizumabandrecurrentposteriorreversibleencephalopathysyndromeinapatientpresentingwithdeepveinthrombosisacasereportandreviewoftheliterature AT rajeshbelani anassociationbetweenbevacizumabandrecurrentposteriorreversibleencephalopathysyndromeinapatientpresentingwithdeepveinthrombosisacasereportandreviewoftheliterature AT marklazarus associationbetweenbevacizumabandrecurrentposteriorreversibleencephalopathysyndromeinapatientpresentingwithdeepveinthrombosisacasereportandreviewoftheliterature AT stanleyamundson associationbetweenbevacizumabandrecurrentposteriorreversibleencephalopathysyndromeinapatientpresentingwithdeepveinthrombosisacasereportandreviewoftheliterature AT rajeshbelani associationbetweenbevacizumabandrecurrentposteriorreversibleencephalopathysyndromeinapatientpresentingwithdeepveinthrombosisacasereportandreviewoftheliterature |